The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner with Beam Therapeutics Inc. on developing drugs for rare genetic diseases using base editing, a technology for manipulating DNA.
Gene editing is the next phase of genetic medicine, and another big step was just announced. Monday morning, Pfizer unveiled a $1.3 billion partnership with Beam Therapeutics to develop three treatments for genetic disease in the next four years. They’ll use Beam’s leading-edge technology that makes precise corrections to typographical errors in our genes—a technology called “base editing”.
Beam is a top constituent in the XDNA Index